You can buy or sell GTHX and other stocks, options, ETFs, and crypto commission-free!
G1 Therapeutics, Inc. Common Stock, also called G1 Therapeutics, is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. Read More The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Research Triangle Park, North Carolina
52 Week High
52 Week Low
Yahoo FinanceMay 13
G1 Therapeutics to Present at UBS Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 13, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the UBS Global Healthcare Conference. The presentation will take place on Tuesday, May 21 at 4:00 p.m. ET at the Grand Hyatt New York in New York, NY. To access the live webcast presentation, please visit the Events & Presentations page within the Investors section of the G1...
Seeking AlphaMay 12
G1 Therapeutics, Inc. CEO Mark Velleca on Q1 2019 Results - Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Jeff Macdonald - Head, Investor & Public Relations Mark Velleca - President & CEO Jennifer Moses - CFO Rajesh Malik - Chief Medical Officer & SVP R&D Conference Call Participants Dane Leone - Raymond James & Associates Chad Messer - Needham & Company Harshita Polishetty - B. Riley FBR Operator Good afternoon, ladies and gentlemen, and welcome to G1 First Quarter 2019 Corporate and Fina...
Yahoo FinanceMay 12
Imagine Owning G1 Therapeutics And Wondering If The 48% Share Price Slide Is Justified
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Over the last month the G1 Therapeutics, Inc. (NASDAQ:GTHX) has been much stronger than before, rebounding by 39%. But that doesn't change the fact that the returns over the last year have been less than pleasing. In fact the stock is down 48% in the last year, well below the market return. Check out our latest analysis for G1 Therapeutics G1 Therapeutics didn't have any revenue in ...
Expected Aug 7, After Hours